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ABSTRACT 
Vemurafenib has been approved in the United States for the treatment of 
relapsed or refractory BRAF mutation positive malignant melanoma and is 
being investigated in various other malignancies. The RAS/RAF/MEK/ERK 
(MAPK) pathway is critical to cell proliferation in many human cancers. The 
mTOR inhibitors are well known to exert profound anticancer effects across 
malignancies through inhibition of the PTEN/PI3K/AKT/mTOR (mTOR) 
pathway. We hypothesize that the toxicity profile of the combination of 
vemurafenib and everolimus will be well tolerated. The primary objective 
is to find the maximum tolerated dose (MTD) and the toxicity of the 
combination of vemurafenib and everolimus following a standard 3 + 3 
design. The most common diagnosis was melanoma in 5 out of 10 patients 
7 
 
(50%). Male patients in 7 out of 10 patients (70%). The average age was 
63.5 years. Two out of 10 patients (20%) had partial responses and an 
additional 2 out of 10 patients (20%) had stable disease. 
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SPECIFIC AIMS 
(I) Background and significance: Vemurafenib has been approved in 
United States for treating relapsed/refractory BRAF mutation positive 
malignant melanoma and is being investigated in various other 
malignancies. The RAS-RAF-MEK-ERK (MAPK) pathway has been deemed 
critical to cell proliferation in several human cancer models. The 
frequency of such BRAF activating mutation and the resultant oncogene 
addiction makes mutated BRAF an extremely attractive target. Combining 
multiple agents with different mechanisms of action is now a paradigm in 
oncology phase I clinical trials. The BRAF inhibitor vemurafenib has been 
selected as the backbone of this trial. The mTOR inhibitors, such as 
everolimus and temsirolimus, are well known to exert profound 
anticancer effects across malignancies via inhibiting the PTEN-PI3K-AKT-
mTOR (mTOR) molecular axis. It is possible that combining an inhibitor of 
BRAF plus an inhibitor of mTOR will be synergistic and might assist 
overcoming resistance to single agents targeted individually to the mTOR 
or MAPK signaling pathways. To our knowledge, there are no clinical 
trials currently evaluating such combination. Therefore, we have designed 
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a phase I trial evaluating such therapeutic combination in patients with 
advanced cancer. 
(II) Hypothesis: We hypothesize that the toxicity of combined vemurafenib 
plus everolimus will be well tolerated. 
(III) Specific aims:  
Primary Objective: To determine the maximum-tolerated dose (MTD) of 
combined of vemurafenib and everolimus. 
Secondary Objective: To describe preliminary antitumor activity (tumor 
response) of the combination of vemurafenib and everolimus. In the MTD 
expansion phase, correlate responses to treatment with mutations in the 
PTEN-PI3K-AKT-mTOR (mTOR) and/or RAS-RAF-MEK-ERK (MAPK) 
signaling axis and/or other signaling aberrations. 
(IV) Brief methodology: The definition of dose-limiting toxicity (DLT) is 
any grade 3/4 that is non-hematologic; or any grade 4 hematologic side 
effect lasting two weeks or longer. Three patients will be treated per dose 
level with standard 3 + 3 design; three individuals will be dosed at dose 
level I and assessed for toxicity. If 0/3 individuals undergo DLT, the next 
3-patient cohort will be dosed at the next higher level. If 1 of 3 
15 
 
individuals (1/3) dosed at a particular level undergoes DLT, then 3 more 
individuals will be dosed at the same dose. In summary, MTD is the 
highest level assessed with a DLT incidence lower than 33%.  Patients will 
continue on the study until their disease has progressed, they elect to 
come off the study, they experience unacceptable toxicities. 
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INTRODUCTION: 
 
The PTEN-PI3K-AKT-mTOR (mTOR) and RAS-RAF-MEK-ERK (MAPK) 
signaling axis (Figure 1) have been deemed key contributors to tumor growth and 
are among the most frequently activated in cancer. The RAS-RAF-MEK-ERK axis 
is one of the critical paths in neoplasia which may be constitutively activated via 
modification of particular proteins, as BRAF, that phosphorylates MEK on 
particular regulator residues as serine. Reports of mutated BRAF mutations have 
been mentioned at high frequency in multiple neoplastic disorders (e.g. 60% of 
melanoma [1], 30% to 50% in papillary thyroid cancer, 5% to 20% in colorectal 
cancer, and approximately 30% in ovarian cancer). Approximately 80% BRAF 
mutations that happen in human neoplastic disorders are characterized by mutated 
exon 15 resulting in the amino-acid V600E [1]. Such mutation imitates regulatory 
phosphorylation which intensifies BRAF activity ten-fold versus wild-type BRAF [1]. 
The frequency of this activating mutation and the resultant oncogene addiction 
makes mutated BRAF an extremely attractive target. Another putative RAF 
inhibitor, sorafenib, has achieved regulatory approval. However, it lacks specificity 
and potency against BRAF and its clinical activity is most likely due to inhibition of 
other targets. Other BRAF inhibitors have recently entered clinical trials, although 
vemurafenib was the first BRAF inhibitor that obtained FDA approval for BRAF 
mutated refractory malignant melanoma. 
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Figure 1. The PTEN-PI3K-AKT-mTOR (mTOR) and RAS-RAF-MEK-ERK (MAPK) 
signal axis. From Tsimberidou, Targeted Therapy in Translational Cancer 
Research, 1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with 
permission from Rightslink. 
18 
 
 
As a proof-of-concept, BRAF inhibition has been effective in other 
conditions as Hairy cell leukemia (Figure 2) [2] and Erdheim-Chester disease [3]. 
We attempted BRAF inhibition with vemurafenib in one patient from our 
retrospective review of our database of patients with Erdheim-Chester disease 
(Table 1) [3]; nevertheless therapy had to be halted due to toxicity. Haroche et al. 
has found BRAF mutations in 54% of cases of Erdheim-Chester disease and 
attempted BRAF inhibition in 2 patients with substantial and rapid clinical and 
biological improvement [4].  
 
Activating mutations specific to the MAPK pathway affect the BRAF, GNAQ, 
and GNA11 genes (mutations frequently observed in melanomas and colorectal 
cancer), whereas mTOR pathway-specific alterations include PTEN and TSC1/2 
loss, as well as activating mutations or amplification of PI3K (observed in various 
cancers). The mTOR and MAPK pathways are interconnected by homeostatic 
feedback loops resulting compensatory activation of one of the pathways in 
response to inhibition of the other. Cancer-driving receptor tyrosine kinases 
(EGFR, HER2, cMET, c-KIT) and the downstream effector RAS signal through 
both pathways simultaneously, and double mutations in the components of both 
pathways and/or concurrent up-regulation are frequently observed in associated 
tumors. 
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Figure 2. Pathology slides showing Hairy cell leukemia status post vemurafenib. 
Bone marrow (panel A) displays hairy cells. Four months later, bone marrow 
biopsy displays decreasing hairy cells from 68% (panel B) to 10-20% (panel C). 
Originally published by the American Society of Clinical Oncology. Munoz J, 
Schlette E, Kurzrock R. J Clin Oncol. 31 (20), 2013 Jul 10:e351-2. Published with 
permission from Rightslink. 
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Table #1 - Fourteen individuals with Erdheim-Chester disease (ECD) or Langerhan 
cell hystiocytosis (LCH). Only patients with adequate follow-up were included. 
Abbreviations: Central nervous system (CNS); female (F); male (M); radiation 
(RT). Reprinted from Mayo Clin Proc, 89(7), Munoz J, Janku F, Cohen PR, 
Kurzrock R. Erdheim-Chester disease characteristics and management, 985-96, 
2014, with permission from Elsevier. Published with permission from Rightslink. 
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Therefore, as supported by the concept of synthetic lethality, simultaneous 
inhibition of the MAPK and mTOR signaling cascades may lead to significantly 
enhanced antitumor activity compared to inhibition of either cascade alone. 
Indeed, preclinical data suggests simultaneous blockade of MEK and mTOR 
substantially enhances antineoplastic action in different tumor xenografts as 
prostate, colorectal, thyroid, pancreatic, and liver cancer. In vitro, cells carrying 
dual mutated PI3K/KRAS show increased sensitivity to combined MEK plus mTOR 
targeted agents.  
 
These findings support the hypothesis that such combination therapy may 
demonstrate activity for various indications, particularly tumor types characterized 
by frequently occurring mutations in the respective pathways. The feasibility of 
concomitant inhibition of MAPK and mTOR pathways is being actively explored 
(http://clinicaltrials.gov), and includes trials of MEK inhibitors GSK1120212 and 
AZD6244 combined with the mTOR inhibitors, everolimus and temsirolimus, 
respectively. Furthermore, mutated PI3K and mutated members of MAPK have 
been frequently found in neoplastic disorders.  
 
For example, mutated PIK3CA coincide with mutated RAS, as KRAS-
NRAS, and mutated BRAF. Janku et al. [5] showed that PIK3CA mutations 
occurred in 54 (11%) of 504 patients tested; whereas mutated BRAF had been 
reported in 31 (9%) of 361 individuals. BRAF mutations were seen in 44% (23/52) 
of patients with melanoma. Regardless of histology, mutated RAS (KRAS, NRAS) 
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or BRAF had been reported in 47% of individuals with mutated PIK3CA versus 
24% wild type PIK3CA. PIK3CA mutations were observed in 20% of individuals 
with mutated RAS or BRAF versus 8% with wild type BRAF or wild type RAS [5].  
 
Everolimus has the same mechanism of action as an immunosuppressant 
and an antitumor agent. Everolimus works via inhibition of mTOR (mammalian 
target of rapamycin) which is a protein kinase implicated in cell cycle control, 
specifically cellular progression from the G1 to S phase. Furthermore, mTOR is 
located downstream from PI3K and AKT. Then eIF4E-binding protein or 4E-BP1 
and p70-S6-kinase (S6K) are located downstream from mTORand subsequently 
translate and regulate mRNAs encoding proteins. The currently FDA approved 
mTOR inhibitors are temsirolimus, which is intravenous, and everolimus, which is 
oral.  
 
The proposed trial seeks to establish the MTD of combined vemurafenib 
plus everolimus in individuals with advanced resistant solid malignancies 
characterized by the prevalence of MAPK and mTOR pathway alterations. In 
addition to clinical safety evaluations, this study provide data regarding 
pharmacokinetics regarding such combination. Pharmacodynamic activity and 
preliminary evaluation of antitumor activity of the combination will be evaluated to 
select indications for further development of the combination in phase II trials. 
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The rest of this chapter named introduction is based upon: Munoz J, Janku 
F, RAS-RAF-MEK pathway: Aberrations and therapeutic possibilities (Submitted 
for publication, Book chapter, Targeted Therapy in Cancer, Wiley). The mitogen-
activated protein kinases (MAPK) belong to a group of threonine- serine kinases 
that form a cascade of molecular signals, eventually leading to proliferation, 
survival, differentiation and cell fate determination [6].  
 
The MAPK network is organized hierarchically (Figure 3) beginning with cell 
membrane receptors subject to external stimuli (such as hormones, cytokines and 
growth factors). These successively initiate proliferation from the cell membrane 
to the nucleus as MAPK’s become phosphorylated by MAPK’s kinases (MAPKK’s), 
which subsequently are phosphorylated by MAPKK’s kinases (MAPKKK’s) that 
further become active via other kinases located the nearby cell membrane [6]. The 
primary MAPK network is RAS:RAF:MEK:ERK [7] axis, composed by Rat Sarcoma 
(or RAS), rapidly accelerated fibrosarcoma (or RAF), MAPK/ERK kinase (MEK); 
plus extracellular signal-regulated kinases (ERK). Once up-regulated, 
carcinogenesis is initiated. An inherited deregulated MAPK pathway, usually due 
to heterozygous mutations [8], causes several phenotypic conditions marked by 
cognitive defects, facial dysmorphism, cardiac defects, and an increased risk of 
malignancies, known as the neuro-cardio-facial-cutaneous syndrome family [8].  
 
Other components of this intricate network (Figure 3) include BRAF (or vraf 
murine sarcoma viral oncogene homolog-B1) [9], whose designation stems from 
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the original identification of RAF during an exploration of retroviral oncogenes. 
Initially RAF-1 was discovered (now called CRAF) in 1985, then ARAF in 1986, 
and subsequently BRAF in 1988 [10].  
 
Hierarchically, the apex of the cascade is composed of HRAS, KRAS, and 
NRAS [10]. The next layer is formed by the MAPKKK, including ARAF, BRAF, and 
CRAF. These can homodimerize or heterodimerize [10]. MEK1 and MEK2 
compose MAPKK, which completes the network with ERK1 and ERK2, and MAPK 
[10]. Although the MAPK network is generally shown as a linear path in cartoons 
(Figure 1), in reality it branches out and interacts with molecular members of other 
pathways including mTOR [11].  
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Figure 3. Simplified diagram of the MAPK signaling pathway. Following stimulation 
of a cell-surface receptor (e.g., KIT), From Tsimberidou, Targeted Therapy in 
Translational Cancer Research, 1st edition. Copyright 2015 by John Wiley & Sons, 
Inc. Published with permission from Rightslink. 
 
Germline mutations in the MAPK pathway are associated with 
developmental abnormalities [12]. Somatic mutations and acquired aberrations in 
the MAPK pathway, particularly RAS and BRAF mutations, are associated with 
malignancies [13]. For example, the MAPK pathway is activated in most 
melanomas [14]. Furthermore, targeted therapy selectively or non-selectively 
inhibiting those aberrations with small molecules has shown benefit [13]. Here, the 
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currently known MAPK pathway mutations and therapeutic possibilities suggested 
by these biomarkers are explicated.  
 
Given the complexity of crosstalk among downstream signals, a working 
hypothesis underlying this phase I study would be that BRAF plus mTOR blockers 
will likely become synergistic. Additionally, combination therapy with drugs that 
target different key signal transduction pathways may help overcome both intrinsic 
and acquired resistance in individuals with prior exposure to RAS/RAF/MEK and/or 
mTOR inhibitors. Furthermore, vemurafenib has been chosen as a BRAF inhibitor 
because of its potency and there is ample evidence in the literature in BRAF 
mutation positive metastatic melanoma to support its efficacy [15]. Additionally, its 
strategic location at the top of the RAS:RAF:MEK:ERK (MAPK) axis is expected 
to benefit and currently no RAS inhibitors are available. Of interest, pre-clinical plus 
clinical trials show that combined BRAF plus mTOR inhibitors is efficacious, 
especially in tumors with co-existing BRAF and PI3K/AKT/mTOR aberrations [16-
19]. 
 
Combining multiple agents with different mechanisms of action is now a 
paradigm in oncology phase I clinical trials. Vemurafenib has received FDA 
approval in the United States for treating refractory BRAF mutation positive 
malignant melanoma and is being investigated in various other malignancies. The 
RAS:RAF:MEK:ERK axis is very important when it comes to cell proliferation in 
many human cancers. The frequency of this activating mutation and the resultant 
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oncogene addiction makes mutated BRAF an extremely attractive target. The 
BRAF inhibitor vemurafenib has been selected as the backbone of this trial. The 
mTOR inhibitors, such as everolimus and temsirolimus, are well known to exert 
profound anticancer effects across malignancies via inhibiting the 
PTEN:PI3K:AKT:mTOR axis [20]. We hypothesize that combining a BRAF plus an 
mTOR inhibitor may be synergistic and assist in overcoming resistance to single 
agents targeted to the PTEN:PI3K:AKT:mTOR (mTOR) and/or 
RAS:RAF:MEK:ERK (MAPK) signal axis. To our knowledge, there are no clinical 
trials currently evaluating such combination. Therefore, we have designed a phase 
one trial evaluating such combination in cancer patients. 
 
 
BACKGROUND: 
 
The RAS family: HRAS, KRAS and NRAS  
 
The rest of this chapter named background is based upon: Munoz J, Janku 
F, RAS-RAF-MEK pathway: Aberrations and therapeutic possibilities (Submitted 
for publication, Book chapter, Targeted Therapy in Cancer, Wiley). The RAS (rat 
sarcoma) genes were named because of the similarity of their sequences to the 
Harvey rat sarcoma virus (or HRAS) and Kirsten rat sarcoma virus (or KRAS) [21]. 
Bos et al. [22] in 1989 reported RAS mutations in pancreatic adenocarcinoma 
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(90%), colon cancer (50%), lung cancer (30%), and thyroid tumors (50%). KRAS 
mutations occur most frequently (approximately 85%), then NRAS (approximately 
15%), and HRAS (less than 1%). KRAS, NRAS and HRAS have a high degree of 
homology and are expressed in many tissues. On average, somatic mutated RAS 
ensue in as many as 30% of malignancies [22], although deregulated RAS 
activation can occur without RAS mutation in the setting of up-regulated upstream 
stimuli signal transducers or down-regulated downstream negative feedback. 
These pivotal RAS molecules are small G proteins, or guanosine triphosphate 
(GTP) / GTP-ases, frontline master regulators activating an intracellular network 
of signals that ultimately lead to gene expression and proliferation. Small G 
proteins also include RRAS, MRAS, Rap-2A, among others [23]. Guanine 
nucleotide-exchange factors (GEF) remove guanosine diphosphate (GDP) from 
inactive GDP-bound RAS. Consequently, RAS has a greater proclivity to bind to 
the more prevalent GTP that then converts into its active form, GTP-bound RAS. 
In summary, RAS proteins are governed via connecting to GTP and/or GDP, that 
subsequently produces active or inactive proteins [24]. RAS proteins are tightly 
regulated, due to a fined tuned balance between GDP/GTP switching, activators 
such as GEF and natural inhibitors such as GTPase activating proteins (GAP).  
 
RAS (HRAS:KRAS:NRAS) can carry aberrations that impair the alteration 
or balance from GTP-active versus GDP-inactive form of RAS. From those 
mutations, Gly12Val is the most frequent HRAS aberration in malignancies, 
accounting for approximately 45% of total somatic HRAS gene mutations. The 
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frequency of particular mutations depends on whether aberrations of a particular 
gene are germline or acquired mutations. Interestingly, germline KRAS mutations 
are rare in human malignancies; where acquired somatic KRAS mutations occur 
far more frequently.  
 
 
The congenital RAS-opathies: Germline mutations of RAS 
 
A phenotypic spectrum is linked to a disturbed MAPK pathway causing 
genotype-phenotype associations such as RAS aberrations [25] and 
neuro/cardio/facial/cutaneous disorders. These are known as RAS-opathies and 
include Noonan syndrome [26] (predisposed to juvenile myelomonocytic 
leukemia), LEOPARD [27], Neurofibromatosis type 1 [28] (predisposing individuals 
to myeloid malignancies such as juvenile myelomonocytic leukemia), Costello 
syndrome [29] (which can result in solid tumors such as rhabdomyosarcoma), 
cardiofaciocutaneous syndrome [30, 31] (associated with acute lymphoblastic 
leukemia), and other Noonan-like syndromes.  
 
Each gene in the MAPK pathway, located on different chromosomes, 
encodes a different protein so it is not surprising that different mutations manifest 
clinically as different diseases [25]. The clinical presentation of these diseases is 
not, however, exclusively associated with a particular mutation in these RAS-
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opathies. An example is the relatively common Noonan syndrome, which has been 
associated with multiple MAPK aberrations (KRAS:NRAS:BRAF:MEK1). The son 
of sevenless (SOS1) gene is a type of GEF, which as explained above, alters the 
GDP/GTP balance involving RAS. Clinical overlap among these hyperactive RAS 
syndromes [32] is likely due to an interplay among multiple members of MAPK. 
Cardiofaciocutaneous syndrome were linked to a varied array of mutated 
KRAS:BRAF:MEK1:MEK2 genes in as many as 90% of patients. One exception is 
a germline missense mutated HRAS proto-oncogene causing confirmed Costello 
syndrome in almost a 100% of affected patients. By the same token, 
neurofibromatosis type 1 (NF1) is secondary to heterozygous NF1 gene loss-of-
function, which regulates expression of neurofibromin, a RAS GTPase, a large 
ubiquitous protein highly expressed in neurons, Schwann cells, and leukocytes 
accounting for the clinical stigmata of neurofibromas. NF1 is a tumor suppressor 
gene and patients are thus prone to second-hit malignancies as neurofibromin is 
a protein with GAP activity (a negative controller of MAPK axis). Patients with type-
1 neurofibromatosis have more benign tumor development called neurofibromas 
and malignancies such as peripheral nerve sheath tumors [33], sarcoma,  GIST, 
and other types of neoplasia [34], and juvenile myelomonocytic leukemia [28]. 
Costello syndrome can present with sarcomas, neuroblastoma, and other types of 
neoplasia [29]. 
 
Even though the genotype-phenotype relationship is not completely clear 
[12], mutations in KRAS affect the skin and may develop leukemia. Mutations in 
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HRAS (such as Costello syndrome) manifest via skin abnormalities and tumor 
growths. For example, patients with Noonan syndrome have a small increased 
likelihood of developing malignancies [35]. LEOPARD syndrome has been 
associated with leukemia, neuroblastoma, and melanoma [35, 36]. 
 
 
The acquired RAS-opathies: Melanoma and NRAS 
 
Once a receptor is stimulated by cytokines or growth factors, the receptor 
gets attached to Src homology 2 (SH2) domain that recruits SOS, subsequently 
disrupting the homeostatic GDP/GTP balance. Cell receptor stimulation causes 
RAS to dissociate from GDP and RAS binding to GTP, activating MAPK pathway 
downstream components including RAF and MEK [37]. RAS activation is restricted 
by GTP-ase activity or GAP’s that balances active-GTP-attached RAS versus 
inactive-GDP-attached RAS. Mutations in RAS proteins change the amino-acids 
(as G12:G13:Q61), modifying hydrolysis from the binding of RAS to GTP, thus 
activating the MAPK pathway. BRAF mutations have been seen in 50 to 70% of 
patients with melanoma [38, 39], whereas somatic NRAS mutations are found in 
15-30% of cases, producing a constitutively active NRAS protein, which stimulates 
the MAPK pathway. It has been suggested that an interaction exists between 
NRAS and c-Met, epidermal growth factor receptor (EGFR), and KIT. Most patients 
with melanoma have a hyperactive MAPK pathway; thus, it is not surprising that a 
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MEK inhibitor such as MEK162 is associated with positive outcomes in NRAS 
mutant melanoma. 
 
 
RAF family: ARAF, BRAF, and CRAF 
 
The ARAF:BRAF:CRAF proteins belong to the serine/threonine group of 
kinases downstream from RAS, and upstream from MEK1/2. Even though 
ARAF:BRAF:CRAF are siblings from a family, they have distinct characteristics; 
BRAF would the powerful stimulator of MEK after comparison versus its relatives, 
ARAF and CRAF. For example, BRAF and CRAF have essential differences in 
binding to RAS [40] and are governed by distinct autoregulatory mechanisms [41]. 
Of the 3RAF isoforms, BRAF is most frequently involved in cancer (approximately 
7% in general and 70% melanoma) [42]. Most mutated BRAF arise within the 
kinase domain, leading to V600E substitute that stimulates MAPK [1]. Somatic 
mutated BRAF were commonly documented in multiple malignancies; 
nevertheless aberrations in ARAF and CRAF are rarely seen. Despite the fact that 
multiple mutated germline BRAF were documented, germline BRAF mutations 
rarely promote tumorigenesis as they do not have the malignant potential of the 
Val600Glu BRAF mutation. Interestingly, germline and somatic amino acid shifts 
may up-regulate or down-regulate the mutant kinase. 
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BRAF inhibitors 
 
Regarding RAF in tumorigenesis, although BRAF is the main RAF subtype 
overall such neoplasia characterize only a portion of malignancies. To further 
complicate this picture, CRAF and BRAF can act in concert through 
heterodimerization (Figure 3). Sorafenib, a RAF inhibitor that also blocks other 
tyrosine kinases along with vascular endothelial growth factor, was not effective 
treating patients with melanoma BRAF V600E mutations and phase three studies 
did not endorse beneficial effects from adding sorafenib to standard of care [43, 
44] despite initial promising results [45]. It may well be that other activated 
pathways such as PI3K will need to be abrogated to produce a more beneficial 
response [46]. Vemurafenib spearheads the list of approved BRAF inhibitors and 
prolonged overall survival (6-month survival rates of 84% versus 64%) compared 
to dacarbazine in BRAF V600-mutant melanoma randomized into the BRIM-3 
study [15], results subsequently confirmed by an extended follow up [47]. Another 
BRAF inhibitor, dabrafenib received FDA approval in U.S. (05/29/2013) to treat 
BRAF V600E mutant melanoma [48]. The approval of dabrafenib was established 
on improved progression-free survival (median 5.1 versus 2.7 months) compared 
to dacarbazine in an international, open-label phase three study in 250 individuals 
with BRAF V600E mutant melanoma [49].  
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Management of melanoma in the era of B-RAF inhibitors 
 
The management of early-stage high-risk cutaneous melanoma with local 
resection plus adjuvant interferon alfa has been described elsewhere [50]. 
Managing metastatic melanoma is however more complicated. Despite the high 
toxicity and low cure rate of high-dose interleukin-2, only recently have newer 
agents revolutionized the management of metastatic melanoma such as the 
immunotherapy ipilimumab, the monoclonal antibody directed against CTLA 4, or 
a targeted therapy as vemurafenib (FDA approved if there is a V600 driver mutant 
in the BRAF gene, which is present in approximately 50% of patients) [51, 52]. This 
approval was based on clinical trials demonstrating prolongation of overall survival 
in this population. The replacement of glutamic-acid by valine at amino-acid 600 
or V600E mutation was found in approximately 80% of cases [52]; whereas the 
substitution of lysine for valine (V600K mutation) was shown in 20% of cases. 
 
To date, no randomized comparison has been undertaken between 
immunotherapy with ipilimumab, high-dose interleukin-2 and BRAF inhibitors or 
the appropriate sequencing of such agents. Nevertheless, it is indicated that all 
patients be assessed, minimally for BRAF mutation, or to test for a more 
comprehensive panel of mutations. If a comprehensive mutational evaluation is 
not available, in the absence of BRAF V600E mutation, screening for non-V600E 
BRAF mutations, other MAPK aberrations (e.g., NRAS) and KIT should be done. 
Just as distinct malignancies based on their organ of origin have different 
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frequencies of a particular aberration (Figure 4) [1]; there are particular phenotypic 
characteristics that correlate with the genotype of patients with melanoma [53]. As 
an example, an acral melanoma may carry a KIT mutation (approximately 15-20%) 
instead of a BRAF mutation. Initial phase two trials of imatinib for unselected 
metastatic melanoma showed limited activity [54-56]; nevertheless a subsequent 
phase two trial with selected individuals harboring a KIT mutation or amplification 
showed 23.3% response [57]. The MAPK pathway and microphthalmia-associated 
transcription factor (MITF) were associated in melanocyte differentiation/survival 
[58, 59]. MITF is phosphorylated by the MAPK pathway [60] and MITF mutation 
has been associated with familial and sporadic melanoma [61]. In addition to MITF, 
specific aberrations have been correlated with particular subtypes of melanoma 
such as BRAF/NRAS in conjunctival melanomas (BRAF mutations in 29% and 
NRAS mutations in 18%) [62], KIT mutations or amplifications in acral (36%) and 
mucosal (39%) melanomas [63], and GNAQ/GNA11 in uveal melanomas (GNAQ 
in 45% and GNA11 in 32%) [64] (Figure 4). Furthermore, BRAF mutations are 
common in vertical growth phase melanoma and metastatic melanoma (62-72%) 
[65], whereas BRAF mutations are rare in radial growth phase melanomas (10%) 
[65] or in in situ melanoma (5.6%) [66]. Finally, mutated BRAF has been reported 
in non-malignant growths (82% in nevi) [9, 66] suggest that BRAF mutations are 
involved in collaboration with other molecular aberrations in carcinogenesis rather 
than being solo founder mutations. As an example, mutant BRAF had been 
reported in 29% of invasive melanoma versus 5.6% of in situ melanomas. Mutant 
NRAS had been described in 5.2% of primary melanomas and in no in situ 
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melanomas [66]. These NRAS & BRAF mutations seem to occur prematurely 
during melanoma-genesis while remaining present during worsening of disease 
[14]. 
 
Figure 4. Genotypes and phenotypes of malignancies expressing BRAF 
mutations. From Tsimberidou, Targeted Therapy in Translational Cancer 
Research, 1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with 
permission from Rightslink. 
 
37 
 
Comorbidities, performance status, drug toxicities, pace of disease 
progression, and presence of brain metastases are factors to be considered in 
choosing the appropriate course of therapy. For example, unfit patients with fast-
paced bulky disease and central nervous disease involvement are unlikely to 
benefit from high-dose interleukin-2, although BRAF inhibition can salvage 
patients in that scenario. Ipilimumab, an antibody-based immunotherapy directed 
against the CTLA-4 checkpoint, may need a prolonged period of time to show 
activity, and would not be appropriate in the setting aggressive disease 
progression. In contrast, BRAF inhibitors are a very attractive targeted therapy in 
melanoma. Both vemurafenib [67, 68] and dabrafenib [69, 70] have reported 
activity with melanoma that invaded the central nervous system.   
 
 
CRAF story 
 
Downstream RAS, such next line of activated molecules includes BRAF and 
CRAF. No reports of activating mutations of CRAF have been documented so far, 
whereas BRAF kinase domain mutations are as common as 50% in melanoma. 
As a result, it has been suggested that there is single-step activation between RAS 
and BRAF, but that multiple-steps might be involved between RAS and CRAF [71]. 
BRAF inhibitor drugs abrogate MAPK in mutated BRAF cell lines, whereas BRAF 
inhibitors may paradoxically stimulate the MAPK pathway within wild-type BRAF 
cells [72-74]. Despite being relatively safe, dermatologic toxicity [75] was seen with 
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these inhibitors. These include cutaneous squamous cell carcinoma in 12% [76], 
sometimes developing within weeks of starting a BRAF inhibitor suggesting 
preexisting RAS mutations in other skin areas due to paradoxical activation of the 
MAPK pathway (HRAS mutations in 41% of 29 samples with cutaneous squamous 
cell carcinoma or keratoacanthomas) [77]. It has been suggested that combining 
a MEK inhibitor and a BRAF inhibitor may decrease toxicity caused by paradoxical 
stimulation of MAPK axis. As a more ominous complication, a patient exposed to 
vemurafenib developed fast worsening of chronic myelomonocytic leukemia 
related to mutant RAS [78]. 
 
 
Primary and secondary resistance to BRAF inhibitors 
 
Despite high initial responses as high as 48% [15], primary and secondary 
resistance to vemurafenib has been reported and most melanoma patients 
exposed to vemurafenib eventually develop resistance (Figure 5). Thus, 
combinatorial trials using BRAF inhibitors as a backbone or small molecules 
targeting other areas of the MAPK pathway are suggested to overcome resistance. 
Tissue samples obtained during the phase two BRIM2 study showed an 
association between decreased ERK phosphorylation and objective responses, 
whereas increased ERK phosphorylation and the development of secondary 
NRAS (Q61) or MEK1 (Q56P) or MEK1 (E203K) mutations were associated with 
acquired resistance [79].  
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Thus, re-stimulation of MAPK seems to develop resistance to drugs that 
abrogate BRAF. Interestingly, resistance hasn’t been linked with developing a 
second mutation that impairs drug binding to BRAF, a mechanism observed in 
other malignancies. Other possible mechanisms that can cause resistance include 
MAPK pathway reactivation via alternative means like insulin growth factor 
receptor-1 (or IGF-1R)/PI3K axis activation [80, 81], PD-L1 expression [82], 
increased cyclin D1 expression [83], elevated CRAF protein levels [84], production 
of shortened forms of BRAF proteins due to aberrant RNA splicing [85], NRAS 
(Q61) mutations [79], MEK1 (Q56P, E203K, C121S, or F129L) mutations [79, 86, 
87], and ERK activation through bypassing mechanisms including COT activation 
and receptor tyrosine kinase as PDGFRβ upregulation [88, 89]. Conversely, 
clinical response associated with BRAF inhibition lead to decreased 
phosphorylated ERK levels [90].   
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Figure five. Mechanistic diagrams regarding resistant malignant cells to BRAF 
inhibition. From Tsimberidou, Targeted Therapy in Translational Cancer Research, 
1st edition. Copyright 2015 by John Wiley & Sons, Inc. Published with permission 
from Rightslink. 
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MEK inhibitors - The MEK family: MEK1 and MEK2 
 
RAS activation is followed by activation of RAF (ARAF:BRAF:CRAF), 
subsequently MEK (MEK1A1/MEK1A2), then finally ERK (ERK1:ERK2). ERK is 
the final step of the pathway and acts upon multiple proteins. MEK1:MEK2 genes 
encode kinases that activate ERK proteins, their only known substrate. MEK 
kinase activity has been documented as inducing proliferation, although no MEK 
mutations have been associated with triggering development of cancer or primary 
resistance to vemurafenib. Interestingly, a MEK1 C121S mutation was recently 
seen in a melanoma case that became vemurafenib-resistant. The mutant had not 
been present before vemurafenib therapy, supporting the role of molecular 
evolution in therapeutic resistance. MEK aberrations have however been linked to 
some neurocardiofacialcutaneous syndromes. In melanoma, the BRAF V600E 
mutation correlates with response to MEK inhibitors in preclinical models and 
clinical studies. Trametinib abrogates MEK1/MEK2 in patients with prior anti-BRAF 
therapy for mutant BRAF V600E/V600K  [91]. Trametinib (2 mg/day orally) was 
FDA approved based on improved PFS (median 4.8 versus 1.5 months) and 
overall survival (6-month survival rate of 81% versus 67%) compared to 
chemotherapy (dacarbazine or paclitaxel) in the phase 3 METRIC study in 322 
individuals that have BRAFV600E–positive advanced melanoma [92]. Individuals 
status post chemotherapy or immunotherapy were included, whereas prior BRAF 
inhibitors were not allowed and no responses to trametinib were observed [93]. 
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Trametinib received FDA approval [91] when combined with dabrafenib for 
initial treatment for mutant BRAF V600E/V600K melanoma. Overall response with 
dabrafenib (150 mg) combined with trametinib (1 or 2 mg) had been reported as 
76% versus 54% with single agent dabrafenib (P=0.03) [94]. Squamous cell skin 
cancer developed not as frequently in the dual drug group compared to 
monotherapy (7% versus 19%), whereas pyrexia developed more often in the dual 
drug combination versus monotherapy (71% versus 26%) [94]. 
 
Other MEK inhibitors under development are selumetinib, MEK162 and 
others [95].  The combination of selumetinib plus dacarbazine was compared to 
single-agent dacarbazine in a phase 2 study with randomization that accrued 91 
BRAF mutant individuals, showing improved progression-free survival (5.6 versus 
3.0 months) but not an improvement in survival [96]. Furthermore, a phase II trial 
assessed MEK162 in 71 individuals with melanoma carrying V600 BRAF (41 
cases) or NRAS mutations (30 individuals) with partial response of 20% in both 
groups (8/41 cases in BRAF mutations plus 6/30 patients in NRAS mutations) [97].  
 
ERK inhibitors 
A novel selective ERK1/2 inhibitor SCH772984 that may work in cases 
resistant to BRAF or MEK inhibitors while producing improvement in xenografts 
[98]. Further data regarding ERK inhibition is eagerly awaited. 
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Implications of aberrations in the MAPK pathway in the management of lung 
carcinoma 
 
Personalization of genotype-driven treatment for metastatic lung cancer is 
promising with multiple driver mutations have been identified such as EGFR, ALK, 
ROS1, BRAF, NRAS, KRAS, among others. BRAF mutants have been reported in 
1-3% of patients with NSCLC [99-101]. The trial testing dabrafenib in BRAF V600E 
metastatic NSCLC is ongoing (NCT01336634). NRAS mutations were seen in less 
than 1% (1 of 195) of NSCLC [102]. KRAS mutants seem to be more common in 
smokers [103]. KRAS mutations were seen in 22% of smokers with lung 
adenocarcinomas, whereas transition KRAS mutations were seen in 15% of non-
smoker patients with lung adenocarcinoma [104]. The effect of mutated KRAS on 
300 of 1,543 individuals with early NSCLC status post adjuvant chemotherapy 
following resection didn’t show a statistically significant differences in survival 
versus wild-type KRAS in pooled-analysis of four clinical studies [105]. In the 
metastatic setting, mutated KRAS conferred a worse prognosis compared to  
mutated EGFR [106], whereas KRAS mutation was prognostic for reduced PFS in 
the ones that received erlotinib-maintenance although didn’t show statistically 
significant difference in survival compared to wild-type KRAS [107]. KRAS 
mutations herald patients with colon malignancies that are resistant to cetuximab. 
Nevertheless, responses to cetuximab were maintained in phase 3 studies of 
NSCLC [72, 108]. In the absence of current KRAS targeted drugs, the therapeutic 
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emphasis for KRAS-mutant lung carcinoma is to target molecules located down-
stream from activated KRAS, which is supported in pre-clinical models [18]. 
Objective responses had been documented in 16/43 individuals (37%) status post 
docetaxel plus selumetinib compared with none of 40 KRAS-mutated individuals 
with advanced NSCLC receiving docetaxel plus placebo [109]. Clinical trials 
evaluating MEK inhibitors combined with chemotherapy in KRAS-mutated NSCLC  
are underway (NCT01192165, NCT01362296). 
 
 
Acquired mutations in the MAPK pathway in other malignancies 
 
Broadly stated, RAS mutations are present in as many as 30% of all 
malignancies [10], whereas BRAF mutations are found in as many as 60% 
(melanomas 60%; thyroid neoplasia 50%; colon malignancies 20%) [10]. 
Activating RAS oncogenic mutations (NRAS, HRAS and KRAS in decreasing 
frequency) are more frequently seen in follicular-subtype thyroid neoplasia (80%) 
than papillary-subtype thyroid cancer (20%) [110]. RAS mutations have been 
linked to worse outcome in thyroid neoplasia [111]. On the other hand, 43.8% of 
500 patients with papillary thyroid cancers were found to have BRAF mutant state, 
which were linked to higher invasiveness [112]. The BRAF V600E mutation has 
been linked with high-risk clinicopathological factors [113] and increased cancer-
related mortality in individuals with papillary-subtype thyroid cancer [114]. BRAF 
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inhibitors explored in preclinical mice models of thyroid carcinoma decreased 
levels of phosphorylated MEK and ERK [115].  
 
 
Erdheim-Chester disease (ECD) has been felt to be characterize as non-
Langerhans cell histiocytosis. Because it could co-exist in the setting of 
Langerhans histiocytosis [116, 117], it is believed that these conditions may 
overlap pathologically and therapeutically [118]. BRAF mutations were found 54% 
(13/24) of patients with Erdheim-Chester disease and [4] in 38% (11/29) to 57% 
(35/61) of patients with Langerhans cell histiocytosis [119, 120]. Subsequently, 
three patients with relapsed mutated BRAF V600E Erdheim-Chester disease 
displayed positive outcomes status post BRAF inhibitor vemurafenib [121]. 
Individuals with classic hairy cell leukemia almost always carry the V600E BRAF 
mutation [122], whereas approximately 50% of variant hairy cell leukemia carry 
MAP2K1 gene (encoding MEK1) mutations [123] instead of BRAF mutations [124]. 
Some have suggested that patients with exon 15 BRAFV600E-negative hairy cell 
leukemia should be screened for exon 11 (F468C and D449E) mutations [72]. 
Case reports of clinical improvement after exposure to the BRAF inhibitor 
vemurafenib have been described [72, 125] and clinical studies are in progress to 
determine the protagonist part of BRAF inhibition for hairy cell leukemia 
(NCT01711632). BRAF kinase mutants have been documented in 4% of multiple 
myeloma [126]. The case report of an individual with mutated BRAFV600E multiple 
46 
 
myeloma documented response to low-dose BRAF inhibition with vemurafenib 
[127]. 
 
 
Big results for small molecules 
 
Although aberrations in the MAPK pathway have been known to contribute 
to deregulated growth, both in inherited developmental disorders and acquired 
mutations, rendering patients prone to malignancies, only until recently have 
inhibitors been developed that match their respective targets. Initial investigations 
on the MAPK pathway were based on pre-clinical models of acute growth factor 
exposure in the lab, which do not correlate with a normal physiological state in 
vivo, hence, the utility of MAPK pathway inhibitors is being tested in the clinic and 
the challenges of developing a state of BRAF inhibitor resistant disease need to 
be studied (Figure 4). Three agents have been approved by the FDA for use in 
BRAF-mutant metastatic melanoma, the BRAF blockers (vemurafenib & 
dabrafenib) and the MEK blocker (trametinib). Further exploration of MAPK 
inhibition in other malignancies is eagerly awaited. Molecular stratification, and 
targeted therapy of the MAPK network poses us for success while offering the 
opportunity to launch a decisive attack against cancer. 
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PATIENTS AND METHODS: 
 
Patient Eligibility: 
 
Inclusion Criteria: 
 
- Confirmed BRAF mutated status.  
- Measurable or non-measurable disease. 
- Individuals with advanced cancer. 
-   Refractory to standard of care.  
- Three weeks post prior treatment.   
- ECOG better than two.   
- Adequate organ and marrow as per standard (e.g. ANC>1.0). 
- Contraception if needed during and thirty days post study. 
- Able to understanding/signing/consenting our study. 
 
Exclusion Criteria: 
 
- Poorly controlled additional conditions.   
- Poor organ function (e.g. creatinine worse than 2.0). 
- Pregnancy. 
- Status pot stem cell transplantation. 
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- Allergy to vemurafenib or everolimus. 
- Recent surgical procedure (within a month). 
- Patients with a baseline QTc > 500 ms. 
 
Treatment Plan: 
 
This is a phase one, single hospital, open-label, dose-escalation trial of 
vemurafenib plus everolimus, dosed in combination to individuals with metastatic 
or advanced solid malignancies. Dose escalation for such study will examine 
eligible patients with various tumor types. The study will be piloted at the MD 
Anderson Cancer Center in Texas. Other premedications may be substituted or 
not used at all based on physician discretion. Patients will continue treatment 
until their disease worsens, their side effects become too severe, the patient’s 
physician feels we shouldn’t continue, or election to withdraw from study. A 
patient may also be discontinued due to a concurrent illness that prevents further 
administration of treatment. Premedication, precautions, route, and schedule for 
each medication are described in the tables below. Each study medication in this 
protocol has been approved by the FDA and is commercially available. Other 
investigational drugs beyond vemurafenib and everolimus are not allowed. 
 
Concomitant medications:  
 
Vemurafenib plus everolimus will be the only chemotherapy drugs (or 
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agents used with anti-neoplastic intent) given in this study.  No other 
chemotherapeutic or anticancer agents may be administered. Individuals will not 
enroll in other clinical protocol that administers a treatment or uses a device as 
treatment while enrolled in this study except for supportive care trials. Irradiation 
is not allowed during the study, except for palliation purpose at the discretion of 
the Investigator. Administration of other chemotherapy, immunotherapy or 
antitumor hormonal therapy during the study is not allowed. Supportive care, 
including, but not limited to, antinausea drugs can be administered if approved by 
the treating physician.  Because all the agents are commercially available and 
are FDA approved drugs, all institution standard guidelines for these drugs may 
be used as per treating physician.  Concurrent treatment with bisphosphonates is 
allowed for patients who received stable doses prior to study entry.  All 
concomitant treatments, including blood and blood products, must be 
documented and recorded. Erythropoietin may be administered as per treating 
physician consistent with local guidelines. Granulocyte stimulating factors should 
be administered according to institutional guidelines. As the proposed agents in 
this trial have extensive metabolism through the CYP450 3A4 substrates, 
patients should have a 5 half-life washout period or 4-week washout period, 
whichever is shorter, prior to receiving the investigational agents. 
Overlapping toxicities for vemurafenib plus everolimus:  Headache (18-
37%). Peripheral edema (15-40%). Rash (20-50%). Diarrhea (20-45%). Fatigue 
(10-30%). Abnormal liver function tests (20-60%). 
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Study schema: 
 
 
 
Table 2. Dose-escalation schedule for vemurafenib plus everolimus (28-day 
cycle). The starting dose level is Level 1.  If all patients tolerate dose Level 1, 
then we will dose escalate to dose Level 2.  However, if dose Level 1 is 
intolerable, then we will de-escalate to dose Level -0.  If dose Level 0 is 
intolerable, then we will de-escalate to dose Level -1. 
 
Pretreatment Evaluation: 
 
- Complete history and physical examination within 2 weeks of C1D1. 
- 12-lead ECG within 4 weeks of C1D1. Vemurafenib can cause Qtc 
prolongation and monitoring is recommended as per package insert. 
- Laboratory studies:  CBC with differential, BUN, creatinine, potassium, 
magnesium, total bilirubin, SGPT [ALT], glucose, triglyceride, cholesterol, and 
urine pregnancy test. Dyslipidemia is a known side effect of everolimus and 
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needs to be monitored as per package insert. 
- Radiologic evaluation of measurable disease and pertinent tumor markers 
within four weeks before starting treatment.  If the patient does not have 
radiologically measurable disease but has cutaneous measurable disease, this 
must be documented at the pretreatment evaluation physical examination. 
 
Evaluation during study: 
 
- Physical examinations at least once per cycle (28 days). This includes 
skin examination every 2 cycles. 
- Labs should be performed at least once per cycle including CBC with 
differential, BUN, creatinine, potassium, glucose, triglycerides, cholesterol, total 
bilirubin, and SGPT [ALT]. 
- Radiologic evaluations and pertinent tumor markers will be repeated after 
two cycles of treatment.   
- ECGs monthly for three months then q3 months.  
 
Evaluation of Toxicity: 
 
- The MTD will be defined by DLTs that occur in the first cycle (induction 
phase). All enrolled participants will be considered in the DLT analysis. 
Neupogen/neulasta are allowed in this trial. Correctable electrolyte imbalances 
and alopecia are not considered DLTs.  
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- Three individuals will be dosed per level.  If there are no side effects, the 
next cohort will be treated with a 100% increment.  If there is Grade 1 toxicity, a 
50% increment will occur.  If there is Grade 2 toxicity, a 25% increment will occur.  
If there is Grade 3 or 4 toxicity due to study drug, there will be an expansion to 
six patients.  If no other individuals have Grade 3 or 4 side effects, then next 
cohort will be treated with a 25% dose increase.  If a second patient has Grade 3 
toxicity, then the MTD is exceeded.  The next lower dose level will be expanded 
to six patients.  The MTD is the highest level with less than 1/6 individuals with 
Grade 3 or higher toxicity. 
- Patients will continue on the study until their disease has progressed, they 
elect to come off the study, they experience toxicities that warrant coming off 
trial.  
-  No maximum number of cycles if benefiting clinically. 
- If a response has been observed in a particular tumor type with the study 
drug or drug combination, then the study may be expanded to include a total of 
14 participants with that tumor type.  All enrolled participants will be considered in 
the DLT analysis.   
- Up to 3 additional patients may be added to a cohort for evaluation of 
correlative studies.   
 
Response Criteria: 
 
While primary objectives of this study include the evaluation of dose-ranging 
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experience and the toxicity observed, an attempt to evaluate efficacy will require 
the following criteria for response. Patients with lymphoma will be measured per 
the CHESON criteria and all others will be evaluated with the RECIST criteria. 
For details of the CHESON criteria and RECIST criteria, please see Appendix A. 
 
Criteria for Removal from the Study: 
 
- If a Progression of disease per WHO or RECIST criteria as described 
previously. (Exception: If the patient is deriving clinical benefit). 
- The development of unacceptable toxicity. 
- Physician recommendation for patient removal. 
- Patient elects to discontinue further treatment on the study medications. 
 
Reporting Requirements: 
 
Evaluation of Toxicity/Adverse Events: Evaluation of toxicity during the conduct 
of the study will be done following the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE). Known grade I and II toxicities 
and all clinically insignificant toxicities will not be tabulated for FDA approved 
drugs. The study uses FDA approved agents with known toxicity profiles.  
Therefore, Grade 1 and 2 toxicities (related or unrelated) will not be collected or 
documented as these are not considered clinically significant in this patient 
population and/or they are expected for these study agents.  Grade 3 and 4 
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toxicities that are felt to be treatment related and unexpected (per package 
insert) will be documented.  Unless otherwise documented in the electronic 
medical record as clinically significant and study drug related, all lab 
abnormalities will be assumed to be related to the patient’s other co-morbid 
conditions, prior therapies, other concomitant therapies/medications, or 
underlying cancer. Serious Adverse Events will be reported per standard IRB 
reporting requirements. Serious Unexpected problems will be reported per 
standard IRB reporting requirements. Assessment of Intensity: Maximum 
intensity should be assigned to an adverse experience.  Intensity will be assigned 
a Grade of 1-5. Final arbitration of intensity in cases of differing assessments by 
different practitioners will be the attending physician. Day to day fluctuations of 
intensity may not be recorded but rather the worst grade over the longest time 
period.  
      
Statistical Considerations: 
 
- This is a descriptive study with no formal statistical hypothesis to test. 
- This protocol will utilize a standard 3 + 3 design. 
- If a response has been observed in a particular tumor type with the study 
drug or drug combination, then the study may be expanded to include a total of 
14 participants with that tumor type.  All enrolled participants will be considered in 
the DLT analysis.  If at any time more than or equal to one-third of the 
participants at a level develop DLT, that dose is above MTD.   
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-  Patients can be added at the highest dose level seemed safe to date. All 
patients are considered in the DLT analysis. Up to 3 additional patients may be 
added to a cohort for evaluation of correlative studies.  These patients will be 
considered in the DLT analysis. 
- There will be no intra-patient dose escalation.   
- Expected sample size.  Approximately up to 35-45 patients will be treated 
in this study including patients treated in dose expansion cohort at MTD. The 
estimated accrual rate is 1-3 patients per month. 
 
Dose Delays and Modifications: 
 
- If Grade 3 toxicity occurs (DLT), dose reduction by 50% is allowed after 
patient recovers.  The drug that will be reduced is the one that the physician feels 
has most likely caused the toxicity.  If the drug that caused the toxicity is not 
known, the patient will be dose reduced to the previous dose level.  
- If Grade 3 o/4 toxicity that is known to be related to one drug in the 
regimen, then that drug may be de-escalated to the prior dose level after the 
patient recovers to </= Grade 1 toxicity. 
- If Grade 3/4 toxicity for which it is unclear which drug is the cause of the 
toxicity, then the drug which was dose escalated at the current dose level may be 
de-escalated to the prior dose level after the patient recovers to </= Grade 1 
toxicity. 
- If Grade 3/4 toxicity at level one, and if the toxicity is known to be related 
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to one drug in the regimen, then a dose reduction of 50% of that drug is 
permitted after the patient recovers to </= Grade 1 toxicity. 
- If Grade 3/4 toxicity at level one, and if it is unclear which drug is the 
cause of the toxicity, then a dose reduction of 50% of all drugs in the regimen is 
permitted after the patient recovers to </= Grade 1 toxicity. 
 
Correlative Studies (optional): 
 
This phase I study will utilize novel technologies to analyze key 
downstream pathways efficiently so as to provide high impact data that may 
further expand our understanding of the biology of BRAF activation.  Two major 
pathways appear to be involved in downstream signaling.  The PI3K [128] and 
the MAPK axis are involved in proliferation and cell cycle progression.  
Aberrations in the PI3K/AKT/PTEN/RAF/RAS/GNAQ and related pathways may 
be assessed in tumor tissue or circulating blood. 
 
Calendar: 
 
Baseline assessment led within 14 days before C1D1. Baseline screening 
imaging can take place up to 4 weeks before the protocol starts. If screening 
procedures were performed within 7 days prior to Cycle 1 Day 1 it may be 
counted as baseline visit and Cycle 1 Day 1 labs and exams may not have to be 
repeated. Routine lab studies, physical exams, vital signs, weight, performance 
57 
 
status and scans will have a flexibility window of +/- 7 days.   
 
 
 
Table 3. Study calendar. 
 
• Physical examinations at least once per cycle.  ECG at least once per 
cycle per vemurafenib’s package insert. 
• Labs should be performed at least once per cycle including CBC with 
differential, BUN, creatinine, potassium, glucose, triglycerides, cholesterol, total 
bilirubin, and SGPT[ALT]. 
• Radiologic evaluations and pertinent tumor markers will be repeated after 
two cycles of treatment.   
• Testing and drug administration will take place as per protocol schedule 
unless patient/logistical/medical reasons intervene. 
• Note: Evaluation that can occur once per cycle can be done at any point in 
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the cycle. 
 
PRELIMINARY RESULTS: 
 
This study has so far enrolled 10 patients as of April 2014 (Table 4). The most 
common diagnosis was melanoma in 5 out of 10 patients (50%). Male patients in 
7 out of 10 patients (70%). The average age was 63.5 years. The average 
number of cycles on study was 3.2 and the average duration on study was 102.8 
days. All patients had BRAF mutations (Table 5), particularly BRAF V600E 
mutation in 8 out of 10 patients (80%). Two out of the 10 patients (20%) had 
partial responses and additional 2 out of the 10 individuals (20%) displayed 
stability on imaging studies. Five patients out of 10 (50%) had received 
vemurafenib previously (Table 6). The two patients that displayed partial 
responses did not have melanoma (they had papillary thyroid cancer and 
NSCLC, respectively) with none of them had not received vemurafenib 
previously. The 77-year-old male with papillary thyroid carcinoma was 
chemotherapy and BRAF inhibitor naïve prior to receiving vemurafenib plus 
everolimus displaying a 36% response as per RECIST 1.1 (Figure 6). The 55-
year-old female with NSCLC status post multiple lines of chemotherapeutic 
agents and also the BRAF inhibitor dabrafenib prior to starting vemurafenib plus 
everolimus displaying a 39% response as per RECIST 1.1 (Figure 7).   
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Case Diagnosis Age Gender Dose (mg) Cycles Duration (days) Response 
1 Melanoma 65 M 720/5 8.00 224.00 SD 
2 Melanoma 68 M 720/5 3.00 96.00 PD  
3 Melanoma 45 F 720/5 2.00 57.00 PD 
4 Colorectal 63 M 720/5 3.00 99.00 PD 
5 Melanoma 77 F 720/5 1.00 45.00 PD 
6 Appendix 78 M 720/5 5.00 154.00 SD 
7 NSCLC 55 F 720/10 4.00 132.00 -39% 
8 Melanoma 66 M 720/10 1.00 30.00 PD 
9 Esophagus 41 M 720/10 1.00 49.00 PD 
10 Thyroid 77 M 720/10 4.00 142.00 -36% 
 
Table 4. Characteristics of patients enrolled. M: Male. F: female. SD: Stable 
disease. PD: Progressive disease. Cycles: Number of cycles. Response: Best 
response. Appendix: Appendicular carcinoma. Thyroid: Papillary thyroid 
carcinoma. NSLCL: non-small cell lung cancer. 
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Case Response Mutation analysis 
1 SD BRAF V600E 
2 PD  BRAF V600K, MET T1010I 
3 PD BRAF V600E 
4 PD BRAF V600E, SMAD4 P356R, TP53 R213*, KIT M541L 
5 PD BRAF V600E, CDKN2A R58*, PIK3CA E545K, MET N375S 
6 SD BRAF V600E, TP53 R110L 
7 -39% BRAF V600E, IDH1 R132C, PPP2R1A R183 
8 PD BRAF V600E, KIT M541L 
9 PD BRAF Q609*, KRAS A146P, FBXW7 S478F, KIT G498S, KIT M541L, 
STK11 D23E 
10 -36% BRAF V600E, PIK3CA H1047R, RET Q626K 
 
Table 5. Relationship between responders and mutational status. Response: 
Best response. SD: Stable disease. PD: Progressive disease. 
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Case Response Previous therapies 
1 SD Cisplatin, vinblastine, and dacarbazine; vemurafenib 
2 PD  Dacarbazine, vinblastine, cisplatin, IL-2 
3 PD Cisplatin, bendamustine, dacarbazine; ipilimumab; IL2; 
carboplatin, paclitaxel;  vemurafenib 
4 PD FOLFOX, bevacizumab; FOLFIRI, cetuximab; mitomycin-C; 
FOLFIRI, cetuximab; vemurafenib 
5 PD Vemurafenib; trametinib and dabrafenib 
6 SD FOLFOX; FOLFIRI 
7 -39% Carboplatin, paclitaxel; erlotinib; pemetrexed, rituximab; 
vinorelbine; gemcitabine; dabrafenib; MDX 1105 (anti-PD-L) 
8 PD Temozolomide, ipilimumab; GSK1120212 (MEK inhibitor); 
vemurafenib; vemurafenib and sorafenib; carboplatin, paclitaxel 
9 PD Docetaxel, fluoracil, oxaliplatin; irinotecan, cisplatin 
10 -36% Radiation 
 
Table 6. Relationship between responders and previous therapies. Response: 
Best response. SD: Stable disease. PD: Progressive disease. IL-2: Interleukin 2.  
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Figure 6. The 77-year-old male with papillary thyroid carcinoma was 
chemotherapy and BRAF inhibitor naïve prior to receiving vemurafenib plus 
everolimus displaying a 36% response as per RECIST 1.1. 
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Figure 7. The 55-year-old female with NSCLC status post multiple lines of 
chemotherapeutic agents and also the BRAF inhibitor dabrafenib prior to starting 
vemurafenib plus everolimus displaying a 39% response as per RECIST 1.1. 
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DISCUSSION: 
 
Searching under the street light: 
 
We have been looking for diagnostic and prognostic cues “where the light 
is” for the longest time in many fields in medicine including oncology. Old age 
and elevated lactate dehydrogenase helped us to understand some conditions 
although most patients were still treated blindly with non-targeted cytotoxic 
chemotherapy in the absence of better stratification models. Cytogenetics, able 
to assess large chromosomal structure deviations, heralded a step forward. At 
the end of the day, a very small group of patients respond dramatically to non-
targeted cytotoxic chemotherapy in most malignancies when we are shooting in 
the dark; whereas a relatively larger group of patients respond to matched 
targeted treatments while avoiding therapeutic misses or near-misses under the 
bright shining light of molecular profiling. Time and scientific progress brought 
upon us multiple novel molecular profiling platforms that have facilitated the 
process of finding the right treatments for the right subgroups of patients. As a 
disclaimer, some profound responses seen in the targeted era are short-lived 
and perhaps combinatorial trials will overcome therapeutic resistance in the 
years to come.  
 
Cancer is not only one disease. For example, ALK altered neoplasia 
("ALK-oma") is approximately four percent of lung carcinoma. Matching drugs to 
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targets showed impressive results, albeit brief, hence it has been suggested that 
combination therapy will be needed to overcome resistance to single agents 
[129].  
 
Targeting the MAPK & mTOR: MAPK is a group of serine/threonine 
kinases that form a cascade of molecular signals that eventually lead to 
proliferation, survival, differentiation and cell fate determination. The MAPK 
network is organized hierarchically starting at the level of the cell membrane 
receptors with external stimuli (as hormones, cytokines and growth factors) 
successively communicating a message of proliferation all the way to the nucleus 
as MAPK’s, MAPKK’s, and MAPKKK’s. The main identified MAPK network is the 
pathway conformed by RAS-RAF-MEK-ERK, and, if up-regulated, it leads to 
carcinogenesis. Inherited deregulated MAPK pathway, usually due to 
heterozygous mutations, cause several phenotypic conditions [130] with 
cognitive defects, facial dysmorphism, cardiac defects, and increased risk of 
malignancies; coined as neuro-cardio-facial-cutaneous syndrome family. Other 
players in this intricate network include BRAF with a designation which stems 
from its original identification of RAF during retroviral oncogenes. Initially RAF-1 
was discovered (now called CRAF) in 1985, then ARAF in 1986, and 
subsequently BRAF in 1988. Hierarchically, the top of the cascade is aligned by 
HRAS, KRAS, and NRAS. The next layer is formed by the MAPKKK including 
ARAF, BRAF, and CRAF that may homodimerize or heterodimerize. MEK1 and 
MEK2 line up as MAPKK to culminate the network into ERK1 and ERK2, the 
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MAPK. Despite the fact that we illustrate the MAPK network as a linear path, it 
actually branches out and interacts with molecular members of other pathways 
including mTOR. 
 
Novel molecular testing - Coming of age:  
 
Morphologically, many tumors look alike (i.e. some aggressive lymphomas, 
Ewing sarcomas or desmoplastic small round cell tumors) and, let alone, light 
microscopy would have major difficulties settling this diagnostic matter. 
Diagnostic tools to detect molecular aberrations may detect specific mutations 
already known to be common in a particular malignancy or find previously 
unidentified mutations. Molecular diagnosis include new-comers as transcriptome 
sequencing and proteomics that may also permit the identification of novel 
biomarkers for targeted treatments.  
 
Prognostication - Is LDH still valuable in the molecular era? 
 
Definitively yes (at least at present). Molecular tools are not meant to 
replace clinical and laboratorial variables but rather supplement and enrich the 
information available at reach in each particular case. The ubiquitous elevated 
lactate dehydrogenase (LDH) is a poor’s men prognosticator in both benign (i.e. 
pancreatitis) and malignant (i.e. lymphoma) conditions. The value of age or LDH 
assessing risk and prognosis has been well established over the years in 
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different prognostic scales (international prognostic index, follicular lymphoma 
international prognostic index) [131]. Immunohistochemistry alone will misclassify 
an abundant group of patients; immunohistochemistry plus molecular profiling 
and clinical variables as age or race will be a robust way of understanding a 
patient’s tumor. Mechanistically, whether or not these laboratorial variables (LDH, 
beta-2 microglobulin, albumin, etc.) are superficial surrogates of a much deeper 
biology of the tumor and/or the host remains to be seen. That said, a feeling of 
unfairness settles in when comparing the humble LDH to the power unlocked by 
the prowess in generating data from the human genome project as it is 
identifying candidate genes for genetic cancer predisposition, loss-of-function for 
tumor suppressing genes versus gain-of-function oncogenes as possible targets. 
Furthermore, this loss-of-function for tumor suppressing genes may occur 
secondary to hypermethylating the promoter for that particular gene, abrogation 
of one genetic copy (allele) or loss of heterozygosity, and abrogation of both 
gene copies (parental alleles) or homozygous deletion. Molecular studies are 
meant to compliment, not replace, the breadth of knowledge regarding prognostic 
and diagnostic variables that we already have in hand. 
 
The Vogelstein model - Sequential versus catastrophic aberrations:  
 
The Vogelstein model speaks about a step-by-step malignant evolution 
[132]. The Knudson’s “two-hit” theory speaks about an initial mutation followed by 
a second mutation can develop neoplasia [133]. A similar pattern of a 
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subsequent molecular cascade promoting proliferation has been suggested to 
occur with retinoblastoma, helicobacter pylori, and other infectious agents as 
Epstein Barr virus and human papilloma virus; although it has been difficult to 
confirm. Multiple genetic and epigenetic aberrations following the Vogelstein 
model in colorectal cancer have been tried to apply to other malignancies; 
nevertheless these mutations do not necessarily follow a sequential pattern of 
acquisition and accumulation of molecular abnormalities. The 
adenoma/carcinoma stepwise approach (initiation, promotion, progression) of the 
Vogelstein theory has been challenged as some aberrations are present at early 
stages and no longer found in advanced disease, and the dynamic malignant 
process of de-differentiation/re-differentiation does not seem to be a linear 
process of rather irreversible molecular aberrations. Such bidirectional 
differentiation dynamism is exemplified by beta-catenin as part of the Wnt 
signaling pathway, which under normal conditions regulates embryonic 
morphogenesis depending on a temporal coordination of events; but also when 
hyperactive, perhaps due to molecular perturbations produced by Helycobacter 
pylori, can stimulate proliferation and tumor invasion. 
 
Solid tumors - Much to learn from their hematologic counterparts:  
 
Neoplastic cells convey advantages over the soon-to-be outnumbered 
normal cells resulting in a clonal evolution and expansion of the fittest. BRAF 
mutations are common in some solid malignancies but rare in liquid neoplasms 
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with the exception of Hairy cell leukemia. Trisomy 8 is common in some liquid 
malignancies but rare in solid neoplasms with the exception of desmoid tumors.  
 
Passed discrepancies, the anti-apoptotic family of the B cell 
leukemia/lymphoma 2 or Bcl-2, with their members, Bcl-xL and Bcl-2, has been 
identified in both liquid and solid tumors as head and neck malignancies. Beyond 
AML, multiple molecular markers have appeared in recent times in other 
hematological malignancies as myelodysplastic syndromes (TET2, DNMT3A, 
ASXL1, EXH2, U2AF1, etc.), chronic lymphocytic leukemia (NOTCH1, XPO1, 
MYD88, KLH6, etc.), acute lymphoblastic leukemia (ETV6, RUNX1, 
rearrangements of the cytokine receptor gene CRLF2, alterations of the lymphoid 
transcription factor gene IKZF1 or IKAROS, etc.), and multiple myeloma (FGFR3, 
MMSET, MAFB, etc.). Hematological malignancies are ahead of their solid 
counterparts in part due to the ease of genetic evaluation (e.g. peripheral blood 
assessment). It remains to be seen whether most of these aberrations are 
“driver” mutations creating oncogene-addiction, or mere “passenger” mutations 
admiring the landscape while our patients cruise through the path of molecular 
evolution. Complex as it seems, these multiple aberrations will soon stratify 
patients in different small subsets of mutations and once found to be druggable 
targets, extrapolations may be made across malignancies in clinical trials (i.e. 
BRAF inhibition with vemurafenib in BRAF-mutated Hairy cell leukemia).  
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From myeloma to melanoma and back - More than phonetics:  
 
Most melanomas carry aberrations in MAPK which is a cascade of 
activating phosphorylation including KRAS, BRAF (and/or a parallel path through 
CRAF that requires additional steps for activation), MEK, and finally ERK. The 
microphthalmia-associated transcription factor (MITF), critical in the process of 
melanin production, has been found to be mutated in some instances as well. 
Clinically, melanoma has been divided into cutaneous, uveal and acral/mucosal. 
Molecularly, these clinical subgroups have their own characteristic aberrations as 
BRAF/NRAS mutations, GNAQ/GNA11/BAP1 or BRCA1-associated protein 1, 
and KIT, respectively. Up close and personalized, melanoma could be tackled by 
targeted inhibition of BRAF, MEK, NRAS, and KIT. MEK inhibitors as trametinib 
and MEK162 have shown responses in patients with melanomas harboring 
BRAFV600 & NRAS mutations. BRAF inhibitors as vemurafenib and dabrafenib 
(GSK2118436) displayed dramatic improvements in BRAF-mutated melanoma. 
Imatinib may have activity in KIT-mutant melanoma although initial trials have 
been disappointing. Interestingly, BRAF inhibition may cause worsening of pre-
existent RAS mutated conditions and newly diagnosed squamous cell carcinoma, 
keratoacanthoma, second primary melanomas and worsening of RAS-mutant 
chronic myelomonocytic leukemia have been described. Not surprisingly, the 
pairing of BRAF plus MEK inhibitors in clinical trials appears to produce less 
dermatologic toxicity perhaps due to further downstream blockade of possible 
escape pathways. As angiogenesis seems to be hyperactive in melanoma, 
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bevacizumab has been evaluated with carboplatin plus paclitaxel. Despite the 
fact that bevacizumab targets the vascular endothelial growth factor or VEGF 
some may argue that we do not really have a molecular target at this point that 
would help us to select patients. Desperate to find a subgroup that will be setup 
for therapeutic success, investigators looked back at the subset of patients with 
elevated LDH only to find overall survival benefit after bevacizumab challenge 
which proves our point that even the most extensive molecular evaluations might 
not completely replace basic laboratorial data. Multiple myeloma has many things 
to learn from melanoma as the search for oncogenic drivers, targeted therapy 
and molecular stratification of patients. Melanoma has many things to learn from 
multiple myeloma as the investigator’s drive to design combinatorial trials to 
overcome resistance as quadruplets (i.e. VCRD or bortezomib, 
cyclophosphamide, lenalidomide, dexamethasone) and then some (i.e. VDT-
PACE or bortezomib-dexamethasone-thalidomide, and cisplatin-doxorubicin-
cyclophosphamide-etoposide). Myeloma trials do not only vehemently group 
drugs together, but they also bring up new agents aggressively to the frontline in 
newly diagnosed patients, instead of waiting for heavily pretreated individuals 
that are less likely to respond, which has allowed them to obtain responses near 
100% and word in the street is that a cure is near for this plasma cell dyscrasia. 
Interestingly, a very small subset of patients (4%) with multiple myeloma will 
carry BRAF mutations [126]. The value of targeting BRAF-mutant myeloma 
patients with BRAF inhibitors is currently unknown. NRAS (24%) and KRAS 
(27%) mutations have been found in myeloma as well. If we erase the arbitrary 
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limits between malignant hematology and oncology, myeloma and melanoma are 
not so far apart beyond linguistic connotations; and a successful therapeutic 
formula may be extrapolated from one disease to another irrespective of its 
chapter in medicine textbooks. 
 
Lung cancer - Divide and conquer:  
 
Multiple drugs have increased the armamentarium against NSCLC 
including erlotinib for EGFR and crizotinib for anaplastic lymphoma kinase (ALK) 
and ROS1 translocation. KRAS mutations are being challenged by selumetinib 
which is an oral MEK inhibitor downstream from KRAS (non-impressive results 
from farnesyl protein transferase inhibitors in NSCLC population so far), PIK3CA 
mutations with ridaforolimus which is an mTOR inhibitor, BRAF mutations with 
vemurafenib which is a BRAF inhibitor, RET translocations with vandetanib 
(multi-tyrosine kinase drug), DDR2 mutation with dasatinib, HER2 expression 
with afatinib which is an EGFR/HER2 tyrosine kinase inhibitor (non-impressive 
results of trastuzumab in the HER2 amplified NSCLC population so far), and 
MET expression with tivantinib which is a MET tyrosine kinase inhibitor. 
Interestingly, crizotinib was originally developed as a MET inhibitor and it seems 
to be active in patients with NSCLC that express MET. Needless to say, crizotinib 
as an ALK inhibitor is also under evaluation in hematologic malignancies as 
anaplastic lymphoma which gave birth to the name of such tyrosine kinase (ALK 
or anaplastic lymphoma kinase).  
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Prognostic versus predictive - The nail and the hammer:  
 
Just as when you choose your specialist in medicine, you choose your 
disease (i.e. an orthopedic surgeon recommending an arthroscopic procedure for 
osteoarthritis). When you have a hammer, everything looks like a nail; thus it is 
not surprising that oncologists have been treating patients blindly with cytotoxic 
chemotherapy for the longest time. Following the above example, 
immunohistochemistry revealing HER-2 overexpressed breast cancer, reminds 
us of the abundant benefits brought upon patients after finding a nail (i.e. the 
abnormal HER-2 pathway) and hammering it at frontline, relapse and even 
during continuation despite progression (trastuzumab, lapatinib, T-DM1). 
Interestingly, a tumor being identified as HER2-enriched subtype (high HER2 
expression and low basal/luminal expression) does not automatically mean that it 
is a clinically HER2 overexpressed breast cancer. On the other hand, some 
HER2-enriched subtype tumors are clinically HER2-negative breast cancers and 
the possible use of HER2 as a therapeutic target in such population is under 
evaluation. At the end of the day, it makes sense that the evaluation of multiple 
genes involved in the production of a protein (i.e. HER2 hormonal receptor) might 
be a more thorough assessment than the evaluation of an abnormality by a 
single immunochemistry stain (HER2 positivity 2+). HER2-overexpression has 
been a well-known factor heralding poor prognosis (i.e. increased brain 
metastasis, shorter survival, etc.), although it is until the development of HER2-
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targeted therapy that a negative factor became a positive predictive one. 
Similarly, AML has new poor prognostic aberrations (i.e. FLT3) and perhaps it 
will be under the development of novel drugs (i.e. novel FLT3 inhibitors as 
quizartinib) that a negative factor will become a positive one. From a therapeutic 
point of view, discovering targeted therapy directed against the ubiquitous p53 
and KRAS mutations may become the “holy grail” for multiple tumors, including 
gastrointestinal malignancies, nevertheless currently they remain in the dark. 
With the arrival of more refined molecular diagnostic tests, a multitude of nails 
have been brought to our working table; nevertheless at the end of the day 
having endless nails are worthless gadgets without having a hammer to use 
them. It will take time and heavy investment on research to pair druggable 
aberrations to matched targeted therapies. 
 
CML - A full circle:  
 
CML is used across the board as the paradigm of personalized medicine 
and physician-scientists are in a quest to find the next “imatinib-like” agent; 
nevertheless its impressive results, imatinib is not magic and a percentage of 
patients are resistant and ultimately progress. Molecular evaluation was critical to 
understand why this occurred (i.e. T315I mutation) and the development of 
second and third generation tyrosine kinase inhibitor to overcome such 
resistance. Interestingly, the advent of the powerful pan-ABL1 kinase inhibitor 
ponatinib [134] with response rates near 100% in patients with or without the 
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current known resistant mutations makes unnecessary testing for these 
aberrations.  
 
A word of caution: 
 
Targeted single-agent therapy is no panacea. Ovarian high grade serous 
carcinomas also express high levels of estrogen receptors albeit response rates 
to hormonal manipulation have been low (approximately 10%) [135]. Targeting c-
kit in GIST only showed a 38% response [136], and acute myeloid leukemia, no 
clinical responses as single agent maneuver [137], do not yield the same 
responses hence generalizations should be made cautiously. Furthermore, 
sporadic medullary thyroid cancer may show responses to RET inhibitors even 
without RET mutations. Technical limitations may include the fact that gene 
profiles obtained from formalin-fixed samples might not be the same as 
assessing banked frozen tissue. To further complicate the situation, different 
particular platforms have different specific requirements (frozen unfixed sample 
placed, within a brief lapse of time following surgery, in a particular container to 
be sent to a particular molecular profiling company). Profiling different areas of a 
same tumor, or different metastatic sites stemming from a single tumor, might 
provide discordant results due to tumor heterogeneity. Timing (early versus late) 
and location (local versus distant) might also factor in as these variables might be 
a surrogate of the existence of a different disease that evolves over time; thus it 
is critical to apply molecular profiling data to the exact setting that was initially 
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studied. Beyond offering potential targets for treatment selection that can 
augment the chances of observing responses; high-risk versus low-risk 
discordance between molecular and clinical predictors will be expected in a 
subgroup of patients and treatment decisions might be difficult until large 
prospective matters settle this matter.  
 
Personalized cancer drugs with their potent, albeit transient, responses 
may never “cure” patients because cancer genomes are not the only culprit for 
malignant development or poor prognosis. The molecular makeup of the host 
and the tumor microenvironment probably play a role as well. A limited tumor-
only molecular evaluation of genes could potentially misclassify a patient as low 
risk of mortality (i.e. chronic lymphocytic leukemia), when such patient actually 
carried high risk variables for heart disease or thromboembolic events, which 
sadly would ultimately cause the patient’s demise in a swift fashion. The new 
molecular technologies will be able to locate minuscule numbers of abnormal 
genes despite being admixed among countless normal genes which will be used 
to our advantage when it comes to screening; although a diagnostic conundrum 
may arise after discovering a new mutation associated with particular genotype-
phenotype malignant presentations in an asymptomatic patient (prophylactic 
surgical removal versus watch-and-worry with aggressive interval screening). 
 
 
 
77 
 
Future directions - On the non-labeling of patients and combinatorial 
clinical trials:  
 
Light microscopy can only illuminate so far when it comes to poorly 
differentiated malignancies. In the case of carcinomas of unknown primary, an 
aberration-specific approach may guide our therapeutic decisions in lack of an 
organ-specific approach. Certain gene expression profiles obtained from tumors 
may guide towards the normal tissue of origin in a site-specific approach. As 
such, a treatment paradigm has risen that knows no boundaries when it comes to 
differentiating malignant hematology versus oncology (i.e. vemurafenib use in 
BRAF-mutant Hairy cell leukemia) or site of origin (i.e. HER2 overexpressed 
gastric cancer as “druggable” aberrations previously believed to be exclusive of 
breast cancer). In the past, familial neoplasms shed light upon the presence of 
inherited genetic germline mutations as trials studied the affected kindred. In the 
future, each individual patient may be a trial of its own as molecular profiling 
might reveal acquired somatic genetic mutations amenable to targeted therapy.  
As a cautionary note, finding a target in a pathway is not a guarantee of 
response. Heavily pretreated PIK3CA-mutated colon neoplasia that received 
trials incorporating PI3K/AKT/mTOR inhibitors showed minimal activity [138]. 
 
Finding an aberrant pathway (i.e. PDGFRA) may unify both common and 
rare tumors and standardize a therapy (i.e. imatinib mesylate for KIT-negative 
GIST, Erdheim-Chester disease, desmoid tumors, and dermatofibrosarcoma 
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protuberans). It has been a decade since the Human Genome Project; 
nevertheless translating such massive collection of information to the clinic has 
remained an elusive goal due to technical and economic issues. In this world of 
instant gratification, molecular profiling and genome sequencing during routine 
checkups will soon no longer be utopia (Illumina Inc., Life Technologies, Oxford 
Nanopore Technologies, Noblegen Biosciences, etc.). As seen through deep 
gene-sequencing, cancer is not only one disease; hence the true challenge will 
be to match a tumor to a drug. Beyond wide genome profiling, high-throughput 
technology will also evaluate proteins (proteomics), or cellular metabolism 
(metabolomics) that can be exploited towards prognostic stratification and 
therapeutic decision-making. At the end of the day, you do not want to treat your 
patients with cancer based on the molecular analysis performed at diagnosis five 
years ago; you want real-time high-throughput molecular data now. 
 
Phase I clinical trial design looking for the maximum tolerated dose comes 
from the original chemotherapy trials; perhaps trials looking for the minimum 
effective dose are more applicable to the era of targeted agents. With limited 
resources, the mathematical number of possible combinations of targeted agents 
is not feasible to pursue unless we have a strong pre-clinical rationale in drug 
development. 
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Conclusion: 
 
Protocol 2012-0153 is currently IRB approved and already enrolling patients to 
determine MTD plus preliminary antitumor activity (tumor response) of the 
combination of vemurafenib and everolimus. Suggested completion timeframe for 
protocol 2012-0153 is within three years of accrual start date. Preliminary data 
from initial ten patients enrolled show encouraging results.   
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APPENDIX: DRUG INFORMATION 
 
Everolimus: 
 
Everolimus (Afinitor®), side effects: Angioedema, marrow suppression, 
generalized/localized edema, azoospermia/oligospermia, infection, malignancy, 
mucositis/stomatitis, nephrotoxicity, noninfectious pneumonitis (which might 
require dosage modification or corticosteroid therapy) and wound healing 
complication. Side effects occurring in more than 10% of cases as follows: 
Cardiovascular: Peripheral edema (4% to 45%), hypertension (4% to 30%). 
Central nervous system: Fatigue (7% to 45%), fever (19% to 32%), headache 
(18% to 30%), seizure (SEGA: 29%), personality change (SEGA: 18%), insomnia 
(9% to 17%), dizziness (7% to 14%). Dermatologic: Rash (18% to 59%), acneiform 
dermatitis (SEGA: 25%; RCC: 3%), cellulitis (SEGA: 21%), nail disorders (5% to 
22%), pruritus (14% to 21%), dry skin (13% to 18%), contact dermatitis (14%), 
excoriation (14%), acne (11%). Endocrine & metabolic: Hypercholesterolemia 
(17% to 77%), hyperglycemia (12% to 75%; Grades 3/4: <1% to 17%), 
hypertriglyceridemia (≤73%), bicarbonate decreased (≤56%), hypophosphatemia 
(13% to 40%), hypocalcemia (17% to 37%), hypoglycemia (≤32%), hypokalemia 
(12% to 23%), hyperlipidemia (renal transplant: 21%), hyperkalemia (renal 
transplant: 18%), dyslipidemia (renal transplant: 15%), hypomagnesemia (renal 
transplant: 14%), hyponatremia (≤16%), albumin decreased (≤13%). 
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Gastrointestinal: Stomatitis (oncology uses: 44% to 86%; Grade 3: 4% to 7%; 
Grade 4: <1%; renal transplant: 8%), diarrhea (19% to 50%; Grade 3: ≤5%; Grade 
4: <1%), constipation (11% to 38%), abdominal pain (3% to 36%), nausea (26% to 
32%: Grade 3: 1% to 2%), anorexia (1% to 30%), vomiting (15% to 29%; Grade 3: 
1% to 2% ), weight loss (9% to 28%), taste alteration (10% to 19%), gastroenteritis 
(1% to 18%), xerostomia (8% to 11%). Genitourinary: Urinary tract infection (renal 
transplant: 16% to 22%; RCC 5%), dysuria (renal transplant: 11%). Hematologic: 
Anemia (26% to 92%; Grades 3/4; 13% to 15%), leukopenia (oncology uses: 26% 
to 54%; renal transplant 3%), and others. Neuromuscular & skeletal: Weakness 
(19% to 33%), arthralgia (≤15%), back pain (11% to 15%), limb pain (10% to 14%). 
Otic: Otitis (SEGA: 14% to 36%). Renal: Creatinine increased (11% to 50%), 
hematuria (renal transplant: 12%). Respiratory: Upper respiratory infection (16% 
to 82%), sinusitis (3% to 39%), cough (7% to 30%), dyspnea (20% to 24%; Grade 
3: 2% to 6%; Grade 4: ≤1%), epistaxis (≤22%), pneumonitis (14% to 17%; Grade 
3: 3% to 4%), nasal congestion (14%), rhinitis (14%), pharyngitis (4% to 11%). 
Miscellaneous: Infection (RCC: All infections: 37%; Grade 3: 7%; Grade 4: 3%; 
renal transplant: 62%).  
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